{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":null,"indication":null,"name":"NCT03534323","nct_id":"NCT03534323","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03534323. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Duvelisib will be given alone for the first seven days. On day 8 Venetoclax will be added.\n\n* Duvelisib will be administered orally twice daily of 25mg\n* Venetoclax will be administered orally daily of 100mg\n* All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation","label":"Phase 1 Level 1: 100 mg Venetoclax (daily) + 25 mg Duvelisib (BID)","type":"EXPERIMENTAL"},{"description":"* Duvelisib will be administered orally twice daily of 25mg\n* Venetoclax will be administered orally daily of 200mg\n* All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation","label":"Phase 1 Level 2: 200 mg Venetoclax (daily) + 25 mg Duvelisib (BID)","type":"EXPERIMENTAL"},{"description":"* Duvelisib will be administered orally twice daily of 25mg\n* Venetoclax will be administered orally daily of 400mg\n* All patients will be admitted for administration of the initial dose of venetoclax at each dose escalation","label":"Phase 1 Level 3: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID)","type":"EXPERIMENTAL"},{"description":"* Duvelisib will be administered orally twice daily of 25mg\n* Venetoclax will be administered orally daily of 400mg","label":"Phase 2: 400 mg Venetoclax (daily) + 25 mg Duvelisib (BID)","type":"EXPERIMENTAL"}],"collaborators":["Secura Bio, Inc."],"completion_date":{"date":"2026-07-01","type":"ACTUAL"},"conditions":["Chronic Lymphocytic Leukemia","Richter Syndrome"],"enrollment":{"count":55,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Duvelisib","otherNames":["IPI-145"],"type":"DRUG"},{"name":"Venetoclax","otherNames":["Venclexta"],"type":"DRUG"}],"last_update":"2026-10-28","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-12-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Complete Response Rate (CRR)","timeFrame":"Response assessment on the end of cycle 3, 6 and 13. With 28 days per cycle."},{"measure":"Overall Response Rate (ORR)","timeFrame":"Response assessment on the end of cycle 3, 6 and 13. With 28 days per cycle."}],"references":[{"citation":"Crombie JL, Ryan CE, Ren Y, Tyekucheva S, Carey C, Zou A, Normilus S, Montegaard J, Bhandari S, Alencar A, Soumerai JD, Arnason JE, Kim AI, Parry EM, Armand P, Fisher DC, Brown JR, Davids MS. A phase 1/2 study of duvelisib plus venetoclax in patients with relapsed/refractory CLL/SLL or Richter transformation. Blood Adv. 2026 Jun 9;10(11):3811-3819. doi: 10.1182/bloodadvances.2025018878.","pmid":"41886642","type":"DERIVED"}],"start_date":{"date":"2018-07-12","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS","url":"https://clinicaltrials.gov/study/NCT03534323"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03534323"}